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THE EFFECTS OF ANDROGEN THERAPY ON THE ENDOMETRIUM OF 
TRANSGENDER MEN 
ANITA SHAH 
ABSTRACT 
 Individuals who identify themselves as transgender have gender identities that do 
not match their anatomical sex. Females who identify as male, also known as female-to-
male transgender (FTM), may opt to undergo hormonal and surgical treatment in order to 
transition to the male phenotype, including high-dose testosterone treatment to develop 
male secondary sexual characteristics and surgical procedures. Currently, the 
recommendation is for the patient to have a hysterectomy within five years of initiating 
testosterone therapy to decrease the risk of developing endometrial cancer. However, 
long-term testosterone treatment has not been proven to cause an increased risk of 
endometrial cancer. With the use of gene expression and immunohistochemical studies, 
this study aimed to show no upregulation of genes associated with proliferation (Ki-67) 
and endometrial cancer (ZIC2) in endometrial tissue from FTM individuals treated with 
long-term testosterone compared to endometrial tissue from postmenopausal women, 
premenopausal women with benign endometrium, and women with endometrial cancer.  
Our findings showed that Ki-67 and ZIC2 expression in the FTM samples was 
significantly lower than in the endometrial cancer samples. Our findings call into 
question the concept that long-term testosterone treatment causes neoplastic changes in 
endometrial tissue and the need for routine hysterectomy in these patients. 
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INTRODUCTION 
Definitions and Terminology:  Transgenderism, Transsexualism, Gender 
Dysphoria, and Gender Incongruence 
 In the simplest form of the word, transsexualism is a subset of transgenderism, 
that indicates cross-gender identification (Meyerowitz). In recent years, there have been 
some discrepancies in the interpretation of the term transsexualism. The term gender 
dysphoria was introduced in 1973 to broaden the definition of transsexualism to include 
any dissatisfaction or discomfort with one’s gender, ranging from non-pathological to the 
most extreme, transsexualism (Fisk). However, in recent years, the definition of the term 
gender dysphoria has also been debated. Some believe gender dysphoria refers to distress 
due to discrepancy in one’s own gender identity and the aspects of the body and 
automatic association with the opposite sex (De Vries, Cohen-Kettenis, and Delemarre-
Van De Waal). Others believe that gender dysphoria refers to more of a subjective 
distress and varying degrees of gender uncertainty along a bipolar continuum with male 
and female poles (Deogracias et al.). 
 These terms assign psychiatric diagnoses to transgender people, as seen in the 
tenth version of the International Classification of Diseases and Related Health Problems 
(ICD-10). Currently, the World Health Organization (WHO) is revising the ICD-10 
terminology. The transgender population has suffered discrimination over the years, in 
part due to their current status as carrying a psychiatric diagnosis. For the subsequent 
ICD-11, the majority of the transgender population has lobbied to change the term 
Gender Identity Disorder to Gender Incongruence, and many do not believe it should 
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remain in the psychiatric disorder section since there are many individuals who present 
for gender reassignment without any distress or impairment. Some believe that a 
diagnosis should not be assigned at all. However, because many healthcare systems 
require a diagnosis for an individual to access care, there are concerns that transgender 
individuals may lose access to healthcare if a diagnosis is not assigned. Therefore, the 
new proposed amendments attempt to provide a classification that will ensure access to 
healthcare while simultaneously altering the diagnosis to recognize the patient’s issue 
rather than pathologize or stigmatize them, as seen in Table 1 (Beek et al.). 
 
Table 1. Proposed Changes by the WHO Working Group on the Classification of 
Sexual Disorders and Sexual Health (WGSDSH) to GIC Classification in ICD-10 
(adapted from Beek et al.).  
 
1.  The diagnosis would no longer be included in the mental health chapter, but be 
part of an independent chapter on sexual health 
2. The ICD diagnostic term to be used would be changed from Gender Identity 
Disorder of Childhood into Gender Incongruence of Childhood 
3.  Stricter criteria for the new diagnosis of GIC would be used in order to reduce the 
risk of false positives 
4.  Distress due to gender incongruence would not form part of diagnostic criteria 			
Treatments Available to Transgender Men 
 This study focuses on transgender men, individuals who are assigned at birth as 
female but who identify themselves as male. These individuals are also known as female-
to-male (FTM) transgender people.  
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 To achieve their desired phenotype, FTM patients may elect to have hormonal 
and surgical treatment. Hormonal therapy includes androgens, either parenteral or topical.  
Gender reassignment surgery includes various procedures to more closely approximate 
male secondary sexual characteristics. 	
Hormone Therapy 
 Hormonal reassignment reduces the secondary sexual characteristics of the 
original sex while simultaneously inducing the secondary sex characteristics of the new 
sex. In FTM individuals, androgens induce virilization including a male pattern of sexual 
hair, deeper male voice, male physical contours, and inhibition of menstruation (Gooren). 
Hormonal therapy includes self-injections of testosterone cypionate or testosterone 
undecanoate (O’Hanlan,	 Dibble,	 and	 Young-Spint). Table 2 shows the types of 
androgens and dosages used for FTM hormonal therapy; masculinizing effects include 
voice deepening, increased aggression, increased libido, prevention of menses, increased 
hirsutism, clitoral enlargement, breast atrophy, redistribution of body fat, increased 
laryngeal prominence, and testosterone elevation to male levels (Alegria). 	
Table 2. Examples of Androgen Treatments for FTM Individuals (adapted from 
Alegria). 
	Testosterone	enanthate		 75-100mg	intramuscular/week	150-200mg	intramuscular/2	weeks	Transdermal	testosterone	patch	 5-7.5mg/daily	Transdermal	testosterone	gel	 5-10mg/daily		
	4 
Surgical Therapy 
 The most common initial surgical procedure undertaken by FTM individuals is a 
bilateral subcutaneous mastectomy with transposition of the nipple-areolar complex. 
Some individuals also receive a hysterectomy with bilateral oophorectomy to align their 
internal anatomy to their external identity. Genital transformation is a more complex 
surgical procedure, involving the implantation of penile and testicular prostheses 
(Monstrey, Ceulemans, and Hoebeke). 
 An FTM patient may choose between two procedures for genital reassignment 
surgery: phalloplasty or metoidioplasty. In a phalloplasty, the skin from the individual’s 
forearm or lower abdomen is used to construct a neophallus, with the vascular supply 
taken from the deep and superficial circumflex iliac vascular systems (Aköz	and	Kargi). 
In a metoidioplasty, the clitoris enlarged by androgen treatment and its surrounding 
vulvar and vaginal skin is used to construct a phallus (Perovic and Djordjevic). The 
phalloplasty bears more of a resemblance to a penis but does not have sensation. With a 
metoidioplasty, however, the individual will have sensation but a smaller phallus.  	
Possible Adverse Effects of High-Dose Testosterone  
 There has been longstanding concern that systemic androgen therapy may result 
in undesirable side effects, including polycystic changes in the ovaries, increase in uterine 
weight, thickened endometrium, or development of adenomyosis, a condition in which 
endometrial glands grow in uterine muscle. Androgen therapy could theoretically also 
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stimulate the endometrium or cause mucometra, the accumulation of fluid containing 
mucin in the uterus (O’Hanlan,	Dibble,	and	Young-Spint).  
 Because androgen therapy upregulates and stimulates both androgen and estrogen 
receptors, it is cause for theoretical concern that androgen receptors are identified in 
increasing concentrations in endometrial hyperplasia and cancer specimens in 
comparison with normal endometrium (O’Hanlan,	 Dibble,	 and	 Young-Spint). It is 
postulated that testosterone from injections may be converted into estrogen by the 
enzyme aromatase, and this excess estrogen would negatively affect the endometrium by 
supporting uncontrolled proliferation. Figure 1 shows the steroid synthesis pathway 
leading to testosterone and estrogen, starting from the hormone DHEA that is ultimately 
synthesized from cholesterol via pregnenolone and 17-hydroxypregnenolone (adapted 
from Kobayashi et al.).  
 
		
 
Figure 1. Steroid Synthesis Pathway of Estrogen and Testosterone, Beginning From 
DHEA (adapted from Kobayashi et al.). 
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 Bukulmez et al reported that aromatase in human endometrium is induced by 
treatment with androstenedione, a steroid precursor of testosterone (Bukulmez et al.).   
They investigated the regulation of aromatase mRNA expression in human endometrial 
surface epithelial cells by steroid hormones to shed light on pathologic states in which 
aromatase is upregulated.  Stimulatory effects of androstenedione, testosterone, and 
estradiol on both aromatase and SF-1 mRNA expression were in turn blocked by the 
estrogen receptor antagonist ICI 182,780 and the aromatase inhibitor fadrozole.  This 
supports the novel concept that androstenedione and testosterone increase local 
production of estradiol that subsequently provides positive feedback via enhanced SF-1 
binding to the CYP19IIa promoter, resulting in the risk of endometrial proliferation. 
Figure 2 shows the significant difference (P < 0.05) between dihydrotestosterone (DHT), 
androstanediol (A-diol), androstenedione with the estrogen receptor antagonist ICI (A4 + 
ICI), estradiol with ICI (E2 + ICI), and androstenedione (A4), testosterone (T), estradiol 
(E2) (adapted from Bukulmez et al.). Thus, it is biologically plausible that long-term 
androgen therapy in FTM individuals may lead to highly proliferative endometrium and 
possibly malignant changes by these mechanisms. 
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Figure 2. mRNA Expression of A. CYP19IIa and B. SF-1 when treated with A4, T, 
DHT, A-diol, or E2 at 10nM Concentration Each. Bars with asterisks and double 
asterisks are significantly different from those of the same symbol between A and B. 
+ sign indicates P value less than 0.05. A4 = androstenedione. T = testosterone. E2 = 
estradiol. DHT = 5α- dihydrotestosterone. A-diol = 5α-androstane-3α. ICI = 
estrogen receptor antagonist. F = aromatase inhibitor fadrozole (adatped from 
Bukulmez et al.).    	
 Due to fears of endometrial hyperplasia induced by androgen therapy, the current 
recommendation for female-to-male transgender individuals who have undergone 
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testosterone treatment is to also have a hysterectomy (O’Hanlan,	 Dibble,	 and	 Young-Spint). The use of laparoscopy, a minimally invasive surgical approach to the pelvis, to 
assist in the hysterectomy helped to preserve tissues that were needed for subsequent 
procedures in female-to-male reassignment surgery (Ergeneli et al.). The 
recommendation for hysterectomy was derived from findings of endometrial hyperplasia 
in two FTM individuals who had been treated with testosterone and undergone 
hysterectomies (Futterweit and Deligdisch). However, recent studies have shown that 
androgen therapy induces a hypoestrogenic state resulting in amenorrhea and ultimately 
endometrial and cervical atrophy as androgens inhibit endometrial cell growth and 
secretory activity through androgen receptor activation (Urban, Teng, and Kapp). This 
data suggests that proliferation may not be a concern for long-term androgen treatment.  
 Two cases of female-to-male transgender individuals who developed ovarian 
cancer raised speculation that their tumors arose due to increased exogenous androgen 
exposure (Hage et al.). It was hypothesized that long-term androgen treatment was 
associated with polycystic ovaries that could increase the risk of ovarian cancer, and that 
androgens would have harmful effects on other reproductive tissues. These two cases 
gave additional support to the recommendation that FTM individuals taking androgen 
therapy should undergo a hysterectomy in order to prevent adverse outcomes from the 
treatment (Hage et al.). However, in 2009, approximately 1 in 30,000 women underwent 
testosterone treatment, and only 0.01% of them reported cancers involving the uterine 
corpus or cervix. Of the gynecological malignancies involving transmen, there were three 
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cases of ovarian cancer, one case of vaginal carcinoma, and one case of cervical 
carcinoma in situ (Urban, Teng, and Kapp).    	
Data on Endometrium from FTM individuals Taking Androgens 
 A single study has indicated that long-term use of testosterone does not have 
negative effects on the female reproductive tract, suggesting that FTM individuals may 
not need routine hysterectomy. In this study, endometrial biopsies were taken from FTM 
individuals who were undergoing testosterone treatment, post-menopausal women, and 
women in the proliferative phase of the menstrual cycle (Perrone et al.). 
 Ki-67, a standard marker to express proliferating cells, was used in 
immunohistochemical studies to show that proliferation in the inactive endometrium of 
FTM individuals is similar to that of post-menopausal women, and endometria from these 
individuals had significantly lower Ki-67 expression than the endometria of women in the 
proliferative phase of the menstrual cycle, shown in Figure 3 (adapted from Perrone et 
al.). Therefore, high dose treatment of testosterone did not stimulate endometrial 
proliferation.  The study concluded that the ratio of estrogen and testosterone had greater 
effects on the endometrium than simply testosterone itself, as seen in Table 3 (adapted 
from Perrone et al.). 
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Figure 3. Percentage of Ki-67 Expression in Endometria. Female-to-male 
transsexuals (FtM), post-menopausal women (M), and women in the proliferative 
stage of the menstrual cycle (PM). (adapted from Perrone et al.) 				
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Table 3. Hormonal Values the Day of Surgery in FTM Patients. Data are expressed 
as median, 25th-75th percentile. * vs. FTM (Wilconox-Mann-Whitney rank sum test). 
N = number of subjects; FTM = female to male; PM = premenopausal women; NA = 
not available. (adapted from Perrone et al.)  
 
Hormones	 N	 FtM	 N	 PM	 P	value*	
Total	T	
(nmol/L)	
24	 12.3	(7.3-22.0)	 5	 1.4	(1.0-1.4)*	 .0001	
Free	T	
(nmol/L)	
18	 15.6	(8.6-26.7)	 NA	 NA	 NA	
Estradiol	
(pmol/L)	
23	 191	(125-288)	 5	 433	(70-580)*	 .01	
Progesterone	
(nmol/L)	
11	 1.9	(1.7-3.1)	 5	 3.8	(1.9-4.6)*	 .04			
Complications of Hysterectomies 
 Hysterectomies, as with any surgical procedure, may be complicated by infections 
that occur in 9-13% of cases depending on surgical route, including vaginal cuff 
cellulitis, infected hematomas, infected abscesses, infections of wounds or the urinary 
tract, and respiratory infection. Another complication of hysterectomy is venous 
thromboembolism, which occurs in 1-12% of women. Less common complications 
include injuries to the genitourinary or GI tract, bleeding, nerve injury, and vaginal cuff 
dehiscence (Clarke-Pearson and Geller).  Due to the risk of surgical complications, if it is 
shown that there is no increased risk of cancer in female-to-male transgender individuals 
treated with androgen therapy, then the practice of routine hysterectomy in these patients 
should be abandoned.  
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STUDY OBJECTIVES 
	
Hypothesis 
 We hypothesize that long-term testosterone therapy in FTM individuals does not 
increase the expression of genes associated with endometrial proliferation and cancer. On 
the contrary, high-dose androgen therapy will decrease endometrial cell proliferation and 
induce endometrial atrophy, suggesting no increased risk of cancer for the FTM 
population, obviating the need for routine hysterectomy with long-term androgen 
treatment.  	
Specific Aim 1 
 The first aim of this study is to measure the expression of Ki-67, a biomarker for 
proliferation as described above, and ZIC2, a gene that is up-regulated in Grade 2 & 3 
endometrial adenocarcinomas, by real-time PCR. RNA will be extracted from archival 
hysterectomy specimens from transgender men, benign hysterectomy specimens, biopsies 
showing endometrial adenocarcinoma, and biopsies showing inactive endometrium 
(Gardner).  We hypothesize that high-dose testosterone treatment will result in atrophy of 
the endometrial lining and will not cause increased expression of Ki-67 or ZIC2.  Thus, 
there will be no evidence of an increased risk in cancer in the endometrial tissues of 
testosterone-treated transmen.  
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Specific Aim 2  
 We aimed to localize the expression of Ki-67 in the endometrium by 
immunohistochemistry in order to confirm the real-time PCR findings.  We hypothesized 
that high-dose testosterone treatment will not increase expression of proteins associated 
with endometrial cancer or cell proliferation.   
 	  
	14 
METHODS 
 
Sectioning  
 Paraffin blocks of female-to-male transgender hysterectomy tissue, cancerous 
endometrial biopsy tissue, and inactive post-menopausal biopsy tissue were sectioned. 
These samples were collected under a protocol deemed exempt by the BUSM IRB 
(Institutional Review Board). The tissue blocks were immersed in buffered formalin for 
24 hours at room temperature. The tissue blocks were sequentially immersed in 70%, 
95%, 100% ethanol, and Pro-par solution as a xylene substitute to dehydrate them. The 
tissue samples were then embedded in molten paraffin. Once the paraffin solidified, the 
tissue blocks were kept at 4°C. Each individual tissue block was cut into 4-6 µm-thick 
sections with a microtome, floated in a 50°C distilled water bath, and then mounted onto 
poly-L-lysine coated slides and dried overnight.  
 
Immunohistochemistry 
 The slides were deparaffinized and rehydrated by immersing the slides 
sequentially in Pro-par, 100% ethanol, 95% ethanol, 70% ethanol, and distilled water, 
each for five minutes. The slides were then washed gently with distilled water to rid them 
of excess ethanol for five minutes.  
 The slides were then placed in a solvent-resistant container filled with 25 mL of 
DakoZar antigen retrieval solution, Diva Decloaker 10x, and 225 mL of distilled water. 
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For antigen retrieval, the container was placed in the DC2002 Decloaking Chamber, 
essentially a pressure cooker, along with 500 mL of water. The lid was secured closed 
and the factory settings set (Figure 4), as adapted from the operation handbook of the 
Decloaking Chamber (Biocare Medical).  
 
 
 
Figure 4. Visual of the Settings of the Decloaking Chamber (adapted from Biocare 
Medical).   
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 After decloaking, the slides were washed gently with distilled water, and the sides 
of the slides were quickly dried off and marked with a hydrophobic pen along the 
horizontal borders of the sections. The slides were then immediately transferred to 
blocking buffer made of 100 mL of 20x Immunocare TBS and 900 mL of distilled water 
for five minutes.   
 The slides were then flicked dry and placed in a humid container. 200 µl of 
blocking solution consisting of a 1:20 dilution of donkey serum in was placed on each 
slide and incubated in the closed container at room temperature for 15 minutes. After the 
incubation, the slides were briefly washed in buffer and then incubated in the container 
with primary antibody, a Ki-67 rabbit antibody (Biocare). Double staining was performed 
with a solution of Ki-67 and cytokeratin 7 (CK7) mouse antibody (a staining control for 
endometrial epithelium, also from Biocare), made with a 1:25 dilution for the Ki-67 and a 
1:20 dilution for the CK7.  Both were diluted with Renoir Red (Biocare) and applied to 
the slides, with approximately 200µL per slide,.  The slides were again incubated for an 
hour in the humid container. The primary antibody was then washed from the slides in 
TBS buffer solution for 10 minutes.  
 The biotinylated secondary antibody, a CY3 (red) conjugated donkey anti-rabbit 
IgG, was diluted 1:1000 in TBS buffer and applied to the slides, with approximately 
200µL per slide.  The slides were incubated in darkness in the humid container for 30 
minutes. The slides were then flicked dry and washed in TBS buffer in the dark for 10 
minutes. An AlexaFluor 488 donkey anti-mouse IgG solution at 1:700 dilution was then 
applied to the slides and these were incubated in the dark for 30 minutes. The slides were 
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then washed in buffer in the dark for 15 minutes flicked dry, and placed onto a clean 
towel. Drops of Vectashield Mounting Medium with DAPI (Vector Labs) were placed on 
each section and cover-slipped. The sections were then stored in the dark in 4°C until 
read. Stained sections were stored for no longer than two weeks.   
 
Fluorescence Microscopy  
   Fluorescence microscopy was performed to compare protein expression in 
control and FTM samples. Proliferating cells were stained red by the binding of Ki-67 to 
CY3. AlexaFluor 488 stained the endometrial epithelia green by binding to CK7. DAPI 
stained the nuclei blue. About 6-7 glands and 500 cells total were counted for each 
section, and a Ki index was calculated to compare the number of proliferating cells to the 
number of total cells counted. The lower the index, the less the proliferation, and vice 
versa.   
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RESULTS 
 
Preliminary Data 
 To address the first aim, RNA was extracted from formalin-fixed paraffin 
embedded archival surgical specimens as listed above, and endometrium was dissected 
out from the hysterectomy specimens. There were 15 hysterectomy specimens from FTM 
patients who were treated with testosterone for over a year. The average age of the 
patients was 37.1, and the average BMI was 31.1. There were six benign hysterectomy 
specimens with the average patient age of 43 and average BMI of 31.1. The four 
adenocarcinoma specimens were Grade 1 and Grade 2 biopsies and hysterectomies, with 
the average patient age of 54.2 and BMI of 44.9. There were also three inactive 
endometrium biopsies from post-menopausal patients with an average age of 49 and BMI 
of 30. Real-time PCR was performed to quantify gene expression of Ki-67 and ZIC2 as 
seen in Figures 5 and 6 (adapted from Gardner).  
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Figure 5. Ki-67 Expression from Real-Time PCR. Shown in female-to-male 
transgender endometrial biopsies (FTM), Benign hysterectomy biopsies (hyst), 
endometrial adenocarcinoma (cancer), and post-menopausal endometrial biopsies 
(inactive). If bars do not have the same symbol, they are significantly different 
(Gardner).        
 
 The Ki-67 expression in the FTM group is not different from the inactive or 
benign hysterectomy groups, but is significantly lower than the Ki-67 expression in the 
adenocarcinoma group (P = .024). 
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Figure 6. ZIC2 expression from Real-Time PCR. Shown in female-to-male 
transgender endometrial biopsies (FTM), benign hysterectomy biopsies (hyst), 
endometrial adenocarcinoma biopsies (cancer), and post-menopausal endometrial 
biopsies (inactive). Bars without the same symbol are significantly different 
(Gardner).       
 
 ZIC2 expression in the FTM group was most similar to the inactive group, similar 
to the pattern of Ki-67 expression. The expression of ZIC2 in FTM was significantly 
lower than that of the adenocarcinoma group (P = .001) as well as that of the benign 
hysterectomy group (P = .049). As expected, there was also a significant difference in 
ZIC2 expression between the cancer and inactive groups (P = .029).  
 The patterns of Ki-67 and ZIC2 expression among the four groups suggest that 
testosterone therapy in transgender men does not increase the expression of genes 
associated with endometrial cancer. This supports the hypothesis that long-term 
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testosterone treatment does not increase the risk of endometrial cancer in transgender 
men. 
 
Information on Participants  
 There were a total of 26 endometrial biopsy samples. Nine of the samples 
belonged to patients who had hysterectomies for benign indications; four were 
hysterectomy biopsies that contained endometrial adenocarcinoma; six samples were 
endometrial biopsies from post-menopausal women; and seven samples were from 
hysterectomies from FTM patients who had undergone testosterone treatment for at least 
one year. 
 In order to gain more of an understanding of how long-term testosterone affects 
the endometrium of female-to-male transgender individuals, data was collected on 
exactly how long the individual was treated for, seen in Table 4. This information was 
collected prior to de-identification of the samples as per the exempt IRB protocol.  It is 
not possible to determine whether duration and dosage of testosterone was associated 
with Ki index in this small sample of patients.  
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Table 4. FTM Testosterone Dosage. This table shows how long each FTM 
participant underwent androgen treatment and with what dosage. It also shows the 
pathology that was seen when the sample was studied, and the Ki index that was 
determined after immunohistochemistry staining was performed.  
 
ID Number Age (yrs) T Dose Duration of 
T 
Pathology  Ki Index 
(%) 
M1 38 200mg/2 
weeks 
10 yrs Fibroid, prolif 
endo 
28.0 
M3 31 200mg/2 
weeks 
2 yrs Weakly prolif 
to inactive 
0.0 
M5 41 100mg/week 2 yrs Polyp 0.1 
M6 58 200mg/2 
weeks 
2 yrs Polyp with 
simple cystic 
hyperplasia 
3.0 
M12 25 75mg/week 5.5 yrs Prolif endo 18.0 
M16 32 100mg/week 2 yrs 3cm 
submucosal 
fibroid 
0.0 
M17 50 100-180mg/2 
weeks 
Unknown Numerous 
fibroids 
12.0 
	
	
Immunohistochemistry Staining 
 Ki-67, a marker for proliferation, was stained red with CY3. The nuclei were 
stained blue with DAPI, and the glands were stained green with CK7. As expected, 
adenocarcinoma glands had high proliferation, as seen in Figure 7. Endometrial glands 
from benign and inactive biopsies (Figures 8 and 9) showed reduced staining of Ki-67, 
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suggesting low proliferation. Some of the benign hysterectomy biopsies showed higher 
proliferation than expected, possibly due to Ki-67 staining in leiomyoma contained in the 
sample. Regardless, the pattern of low Ki-67 staining in FTM samples resembled that 
seen in the inactive specimens and most of the benign samples as well, as seen in Figure 
10.    	  
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Figure 7a. Ki-67 and CK7 Staining of Endometrial Biopsies From a Patient with 
Endometrial Adenocarcinoma at 40x Magnification. Ki-67 staining in red. 
Endometrial epithelial cells were stained green with cytokeratin 7 (CK) antibody, 
while nuclei were stained blue with DAPI.   
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Figure 7b. Ki-67 and CK7 Staining of Endometrial Biopsies From a Patient with 
Endometrial Adenocarcinoma at 40x Magnification.   	  
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Figure 8a. Ki-67 and CK7 Staining of Samples From Two Different Patients Who 
Had Undergone Hysterectomies for Benign Indications at 40x Magnification. A may 
contain leiomyoma. B is a sample from a patient who is in her proliferative phase of 
her menstrual cycle.  
A 
B 
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Figure 8b. Ki-67 and CK7 Staining From Two Different Patients Who Had 
Undergone Hysterectomies for Benign Indications at 40x Magnification. C is a 
sample from a patient in the secretory phase.  
C 
D 
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Figure 9a. Ki-67 and CK7 staining of endometrial biopsies a postmenopausal 
woman at 40x magnification.  Four different patient specimens are included in 
Figure 9.   
	29 
 
 
 
Figure 9b. Ki-67 and CK7 Staining of Endometrial Biopsies From a 
Postmenopausal Woman at 40x Magnification.   
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Figure 9c. Ki-67 and CK7 Staining of Endometrial Biopsies From a Postmenopausal 
Woman at 40x Magnification.  
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Figure 10a. Ki-67 and CK7 Staining of Endometrial Biopsies From Four Different 
FTM Patients Who Have Undergone Long-Term Testosterone Treatment at 40x 
Magnification.  
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Figure 10b. Ki-67 Staining of Endometrial Biopsies From Four Different FTM 
Patients Who Have Undergone Long-Term Testosterone Treatment at 40x 
Magnification.  
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Ki Index  
 Cells were counted from five to six endometrial glands in each sample, sufficient 
to attain an understanding of the section as a whole. The Ki index was achieved by 
counting the number of cells in the gland that expressed Ki-67, stained in red by CY3, 
and dividing it by total number of cells in the gland, counted by nuclei staining blue with 
DAPI. The higher the Ki index for each gland, the higher the proliferation, suggesting an 
increased risk for endometrial cancer. A total of 26 sections were stained:  nine from 
benign hysterectomies, four from biopsies of endometrial adenocarcinomas, six from 
biopsies of inactive endometria, and seven from biopsies of FTM patients who had 
undergone testosterone treatment for over one year. Table 5 shows the Ki index of each 
individual sample of the four groups. Ki indices of the FTM samples and the inactive 
samples were similar. Comparing the Ki indices of the FTM patients with Ki indices of 
the cancerous biopsies shows a significant difference, with the highest Ki index of the 
cancerous biopsy at 63.0% and the highest of the FTM sample at 28.0%.  
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Table 5. Ki Index. In percent, of individual samples from patients who had 
undergone hysterectomies due to benign indications (benign), patients who had 
cancerous biopsies (cancer), post-menopausal patients (inactive), and FTM patients 
who had undergone testosterone treatment for over one year (FTM). 
 
Sample 
# 
Benign  Sample 
# 
Cancer  Sample 
# 
Inactive  Sample 
# 
FTM 
1 78.0  1 48.0  1 5.0  1 28.0 
2 45.0  2 22.0  2 0.8  2 0.0 
3 19.0  3 63.0  3 15.0  3 0.1 
4 25.0  4 26.0  4 0.2  4 3.0 
5 5.0     5 0.8  5 18.0 
6 39.0     6 9.0  6 0.0 
7 24.0        7 12.0 
8 0.5          
9 4.0          
Mean 16.5  Mean 21.5  Mean 8.9  Mean 9.0 
 
 
Statistics  
 The mean Ki index was taken from each group and a nonparametric ANOVA test 
was performed. One-way ANOVA, the Kruskal-Wallis test, was used because it provides 
more certainty in significance when looking at three or more groups by finding the 
average difference between these groups. Because the data was not normally distributed, 
the use of nonparametric tests was used where the data was ranked. Variation among 
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column medians was significantly greater than expected by chance, indicated by the P 
value of 0.0158. The P value is approximated from the chi-square distribution because at 
least one column has two or more identical values, as seen in Figure 11, between the 
Inactive and FTM groups. Performing the nonparametric one-way ANOVA test showed 
that there is a statistically significant difference between all four groups.  
 
 
 
Figure 11. Average Ki Index. In percent, as measuring by immunohistochemical 
staining of patients from four different groups. Total number of samples that were 
included was 26. Benign: biopsies of benign hysterectomies (n = 9). Cancer: biopsies 
of women who had endometrial adenocarcinomas (n = 4). Inactive: biopsies showing 
inactive endometria (n = 6). FTM: biopsies of FTM patients who had undergone 
testosterone treatment for over one year (n = 7). Using ANOVA, P = 0.0158, 
suggesting a statistically significance difference between all groups.   
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DISCUSSION 
 
 Presently, the recommendation for FTM patients who take long-term testosterone 
treatment is to undergo a hysterectomy due to a postulated increased risk of developing 
endometrial cancer. The purpose of this study was to evaluate markers of proliferation 
and cancer to determine whether these are increased by long-term androgen therapy, and 
hence the patients’ risk for cancer. Our hypothesis was that the FTM endometrial samples 
would show no increase in these markers and thus no increased risk of cancer.  If the 
FTM patients have no increased risk of cancer, this would obviate the need for a routine 
hysterectomy in those taking long-term testosterone therapy.  
 Using real-time PCR, our lab had first measured the expression of Ki-67 and 
ZIC2 in endometrial samples from four groups:  FTM samples from transman patients 
receiving testosterone treatment, benign hysterectomy samples, endometrial cancer 
samples, and inactive endometrium samples from postmenopausal women. The results 
from the first specific aim showed that the FTM group differed significantly from the 
cancer group in both Ki-67 and ZIC2 expression. It also showed that the FTM group was 
most similar to the inactive group. These findings supported our hypothesis that the 
testosterone-treated endometrial samples showed no increase in the expression of genes 
associated with proliferation or cancer. 
 The second specific aim, addressed in this thesis, was to perform 
immunohistochemical staining with Ki-67 antibodies to confirm the real-time PCR 
findings of reduced Ki-67 expression in the FTM samples. Out of 26 samples, analysis of 
the Ki indices of all four groups showed that the FTM group was most similar to the 
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inactive group and most dissimilar to the cancer group. This data supports the findings 
from the first specific aim and supports the hypothesis that FTM patients who have 
undergone long-term testosterone treatment are not at an increased risk of endometrial 
cancer and therefore do not need hysterectomy routinely.  
 Without counting the cells, it is evident by simple visual examination that there is 
higher proliferation in the cancer samples than in the FTM samples. A few of the benign 
hysterectomy samples contained levels of proliferation that resembled the cancer 
samples, but this may be due to the fact that some of these endometrial samples were in 
the proliferative phase, or that they were taken from biopsies showing benign tumors 
such as leiomyomas. Regardless, none of the FTM samples resemble these benign cases 
with higher proliferation.  It is biologically plausible that long-term high-dose androgen 
would cause atrophy of the endometrium in the FTM patients similar to the endometrium 
of postmenopausal women.  The synthetic androgen danazol with antiestrogenic and 
antiprogestin effects has long been known to cause endometrial thinning and reduced 
menstrual bleeding in women (Beaumont et al.). 
 The confirmation of the Ki-67 findings of the first aim by data obtained for the 
second aim is evident in Figures 5 and 11. Our results also corroborate the findings of 
Perrone et al, the other study that examined Ki-67 in endometrium from FTM individuals 
on long-term testosterone (Perrone et al.).  However, their study focused only on Ki-67 
staining and did not examine gene expression. 
 Although our findings do support our hypothesis, more samples within each group 
would have strengthened our findings and allowed us to determine whether the Ki index 
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was dependent on dose and duration of androgen treatment in the FTM population. This 
was also a retrospective study with different samples from various years, therefore 
varying quality of tissue samples might have affected the results. However, our CK7 
control staining helped to demonstrate consistency between samples. Future 
immunohistochemical staining for ZIC2 antibodies will be performed to confirm the 
ZIC2 gene expression findings and to establish more support for the hypothesis that FTM 
patients undergoing long-term testosterone treatment are not at higher risk of developing 
endometrial cancer. In vitro cell proliferation experiments (cell counting, MTT assays, 
BrdU assays) with treatment of endometrial epithelial cells with dihydrotestosterone (to 
look at androgen receptor effects) and testosterone (to look at effects not mediated by 
androgen receptor) could be done to examine the effects of these hormones on 
endometrial cell growth. These studies would provide more insight into androgen 
receptor- and non-androgen receptor-mediated effects.  
 In conclusion, my data shows that long-term high-dose testosterone treatment 
does not increase the expression of the Ki-67 gene or protein associated with endometrial 
proliferation in transgender men. These findings support the hypothesis that the risk of 
endometrial cancer is not increased in transgender men treated with long-term androgen 
therapy and should obviate the need for routine hysterectomies and the concomitant risk 
of surgical complications.     
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